DRI is a pioneer and global leader in healthcare royalty monetization with a 32-year history of collaboration with leading biotech and pharmaceutical companies, hospitals, universities and inventors. Between 2006 and 2018, DRI Capital through three managed funds, acquired over 60 separate royalty streams for an aggregate value of over $2 billion on some of the world’s best-selling pharmaceutical products. In 2021 DRI transitioned from a managed fund to a public company structure, through the listing of DRI Healthcare Trust on the Toronto Stock Exchange which subsequently acquired the royalty assets from its managed funds. DRI Healthcare Trust’s mandate is to grow its royalty portfolio and resulting cash flows through a focused acquisition program utilizing the experience and proprietary assets of the DRI team.
DRI Capital is a pioneer and global leader in healthcare royalty investing with over two decades of experience. Since 2006, DRI, through its managed funds, has acquired over $2 billion in royalty streams on some of the world’s best-selling pharmaceutical products. DRI’s funds have collectively acquired over 60 separate royalty streams from inventors, academic and research institutions and life sciences companies, leading the way in the industry with numerous milestone transactions. In 2021, DRI took DRI Healthcare Trust public in the Toronto Stock Exchange.